(Wynnewood, PA) – The Lankenau Medical Center Department of Radiation Oncology has become the first hospital in the Philadelphia region and the 17th nationwide to acquire the BSD hyperthermia system for use in the treatment of cancer. The addition of the system significantly adds to the multidisciplinary arsenal of cancer treatment options Lankenau provides to the Philadelphia and Main Line community.
The BSD Hyperthermia unit delivers precision-focused heat energy to tumors in the body. It is used in combination with radiation therapy and in some instances chemotherapy to enhance treatment effects by making cancer cells more sensitive to radiation. Hyperthermia treatment is typically delivered twice per week prior to radiation treatments.
In Phase III clinical trials where hyperthermia therapy was combined with radiation therapy, hyperthermia improved complete response for recurrent breast, head and neck, melanoma, and other cancers from 23 to 68 percent.
Hyperthermia combined with radiation therapy has also shown improved control rates for patients with advanced cervical cancer.
“We are confident that the addition of hyperthermia to our treatment options will provide significant potential benefits to many of our patients,” says Dr. Marisa Weiss, Director of Breast Radiation Oncology and Breast Health Outreach at Lankenau Medical Center and founder and president of breastcancer.org.
“Main Line Health System treats approximately 3000 cancer patients annually with remarkable results, improving overall survival and quality of life,” said Dr. Albert Denittis, Chief of Radiation Oncology. “We are pleased to be the first hospital in the region to offer this treatment modality to our patients.”
“The Lankenau Radiation Oncology Department has been on the cutting-edge of technology in acquiring weapons to further expand our services in the fight against cancer and hyperthermia furthers this commitment to our patients,” says Gary Antonelli, Radiation Oncology Administrator.
Lankenau Medical Center, a member of Main Line Health, is recognized as a national leader in advancing new options to diagnose and treat illness, protect against disease and save lives. Located on a 93-acre campus just outside of Philadelphia, Lankenau Medical Center is a 389-bed, not-for-profit teaching hospital that includes one of the nation’s leading cardiovascular centers; the Lankenau Institute for Medical Research, one of the few freestanding hospital-associated research centers in the nation; and the Annenberg Conference Center for Medical Education, that trains over 100 new physicians each year through nationally ranked residency and fellowship programs. Lankenau has received both regional and national recognition for its excellence in providing state-of-the-art, quality care. Lankenau Medical Center has been named among the top 10 hospitals in Pennsylvania and top five in the Philadelphia metro area in U.S. News & World Report’s Best Hospitals 2016–2017, and was ranked as high-performing in four specialties: gastroenterology and GI surgery, geriatrics, orthopedics and pulmonology. Lankenau was also ranked as high performing in all nine of the Common Core specialty areas that the publication analyzes, including: abdominal aortic aneurysm repair, aortic valve surgery, COPD, colon cancer surgery, congestive heart failure, heart bypass surgery, hip replacement, knee replacement and lung cancer surgery. Lankenau has achieved The Joint Commission’s Gold Seal of Approval for stroke care and breast cancer care and is one of the nation’s Top Performing Hospitals for heart attack, heart failure, pneumonia and surgical care. Lankenau has also been ranked for multiple years as one of the top 50 cardiovascular hospitals in the nation by Truven Health Analytics. Lankenau has also earned the highest distinction for excellence in nursing care, the American Nurses Credentialing Center Magnet® designation.
© 2016 Main Line Health